On November 20, 2023, Beam Therapeutics Inc (NASDAQ: BEAM) opened at $27.83, higher 11.98% from the last session. During the day, the shares moved up to $31.09 and dropped to $27.59 before settling in for the closing price of $27.47. Price fluctuations for BEAM have ranged from $16.95 to $51.60 over the past 52 weeks.
Annual sales at Healthcare sector company grew by 43193.50% over the past five years. Company’s average yearly earnings per share was noted -1.79% at the time writing. With a float of $68.49 million, this company’s outstanding shares have now reached $71.28 million.
Let’s look at the performance matrix of the company that is accounted for 507 employees. In terms of profitability, gross margin is +62.94, operating margin of -555.61, and the pretax margin is -427.08.
Beam Therapeutics Inc (BEAM) Insider and Institutional Ownership
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Beam Therapeutics Inc is 15.96%, while institutional ownership is 75.14%. The most recent insider transaction that took place on Oct 30, was worth 64,478. In this transaction Chief Medical Officer of this company sold 3,448 shares at a rate of $18.70, taking the stock ownership to the 65,469 shares. Before that another transaction happened on Oct 02, when Company’s Chief Legal Officer sold 388 for $22.85, making the entire transaction worth $8,866. This insider now owns 82,402 shares in total.
Beam Therapeutics Inc (BEAM) Latest Financial update
If we go through the results of last quarter, which was made public on 9/29/2023, the company posted -$1.22 earnings per share (EPS) for the quarter, besting the agreed prediction (set at -$1.36) by $0.14. This company achieved a net margin of -474.54 while generating a return on equity of -37.06. Wall Street market experts anticipate that the next fiscal year will bring earnings of -1.15 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -1.79% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 4.10% during the next five years compared to -84.16% drop over the previous five years of trading.
Beam Therapeutics Inc (NASDAQ: BEAM) Trading Performance Indicators
Check out the current performance indicators for Beam Therapeutics Inc (BEAM). In the past quarter, the stock posted a quick ratio of 4.72. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 30.74.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -4.18, a number that is poised to hit -0.59 in the next quarter and is forecasted to reach -4.70 in one year’s time.
Technical Analysis of Beam Therapeutics Inc (BEAM)
Beam Therapeutics Inc (NASDAQ: BEAM) saw its 5-day average volume 2.25 million, a positive change from its year-to-date volume of 0.98 million. As of the previous 9 days, the stock’s Stochastic %D was 91.09%. Additionally, its Average True Range was 1.96.
During the past 100 days, Beam Therapeutics Inc’s (BEAM) raw stochastic average was set at 85.19%, which indicates a significant decrease from 97.30% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 103.25% in the past 14 days, which was higher than the 68.19% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $22.75, while its 200-day Moving Average is $29.75. Nevertheless, the first resistance level for the watch stands at $32.04 in the near term. At $33.31, the stock is likely to face the second major resistance level. The third major resistance level sits at $35.54. If the price goes on to break the first support level at $28.54, it is likely to go to the next support level at $26.31. The third support level lies at $25.04 if the price breaches the second support level.
Beam Therapeutics Inc (NASDAQ: BEAM) Key Stats
There are currently 81,504K shares outstanding in the company with a market cap of 2.51 billion. Presently, the company’s annual sales total 60,920 K according to its annual income of -289,090 K. Last quarter, the company’s sales amounted to 17,190 K and its income totaled -96,090 K.